Treatment of ®broblasts with the phorbol ester, 12-Otetradecanoyl phorbol 13-acetate (TPA), speci®cally inhibits ®broblast growth factor-2 (FGF-2) induced proliferation. TPA treatment has little or no eect on FGF receptor activation but speci®cally inhibits the activation of p38 MAPK but not other downstream signaling pathways implicated in cell proliferation. p38 MAPK was recently shown to be required for the FGF-2-stimulated proliferation of ®broblasts. The eect of TPA on both p38 MAPK activation and cell proliferation can be reversed by treatment with the PKC inhibitor Go6983. The TPA-mediated inhibition of p38 MAPK activation requires phosphatase activity and is at least partially mediated by ERKs since it is reduced by treatment with the MEK inhibitor PD98059. In contrast, the FGF-2-stimulated dierentiation of PC12 cells, which express the same FGF receptor as Swiss 3T3 ®broblasts, is not aected by TPA treatment, consistent with a lack of involvement of p38 MAPK activity in this process. These data indicate that the eects of TPA treatment on cellular function are not only cell type but also stimulus speci®c and are dependent upon the distinct pathways activated downstream of each stimulus.
Introduction
Basic ®broblast growth factor (FGF- 2 1 ) is one of the original members of an expanding family of heparinbinding polypeptides. Although FGF-2 was ®rst characterized on the basis of its ability to stimulate cell proliferation, it is now known that the members of this growth factor family can modulate a variety of other cellular functions including promotion or inhibition of dierentiation, survival, protease synthesis and secretion and chemotaxis and thereby play critical roles in embryonic development, wound healing and angiogenesis (for reviews see Bikfalvi et al. (1997) ; Szebenyi and Fallon (1999) ). FGFs interact with two classes of receptors: high anity tyrosine kinase receptors (FGFR) and low anity receptors composed of cell surface heparan sulfate proteoglycans (for reviews see Johnson and Williams (1993) ; Klint and ClaessonWelsh (1999) ; McKeehan et al. (1998) ). Four genes encoding distinct but structurally related FGFR have been identi®ed. In addition, alternative mRNA splicing can give rise to a number of variant FGFR. Similar to other growth factor receptors, binding of FGFs to a FGFR results in receptor dimerization and activation of the cytoplasmic tyrosine kinase. Subsequently, speci®c intracellular proteins are recruited to the receptor and serve to activate downstream signaling pathways.
Activation of FGFR can have varying eects depending on the cell type. One of the eects which is common to a wide variety of cell types is the stimulation of cell proliferation. Although FGFR1, FGFR2 and FGFR3 all appear capable of stimulating cell proliferation in the appropriate cell type , the signaling pathways downstream of FGFR1 are the best studied. Nevertheless, it is still not entirely clear how activation of FGFR1 leads to cell proliferation. Furthermore, activation of FGFR1 does not always result in cell proliferation since this FGFR is also required for the dierentiation of PC12 cells (Lin et al., 1996; Maher, 1999) .
Last year, my laboratory showed that the MAPK family member, p38 MAPK, is speci®cally required for the FGF-2-induced proliferation of ®broblasts (Maher, 1999) but not the FGF-2-stimulated dierentiation of PC12 cells. p38 MAPK was also recently shown to be required for the FGF-2-stimulated proliferation of endothelial cells (Tanaka et al., 1999) and mice de®cient in p38 MAPKa are defective in the vascular remodeling associated with angiogenesis in the developing embryo (Mudgett et al., 2000) . However, the signaling pathways linking FGFR1 activation to p38 MAPK activation remain to be determined.
Several years ago it was reported that the protein kinase C (PKC)-activating phorbol ester, 12-O-tetradecanoyl phorbol 13-acetate (TPA), could inhibit the proliferative eect of FGF-2 on vascular smooth muscle cells (Weiss et al., 1995) and endothelial cells (Presta et al., 1998) . In contrast, TPA treatment was found to have no eect on the FGF-2-induced dierentiation of PC12 cells (Sigmund et al., 1990) . Together, these data suggest that FGF-2 stimulated proliferation is speci®cally regulated by a PKCdependent pathway.
The PKC family at present contains 11 dierent members which can be divided into three groups on the basis of structure and cofactor requirements (for reviews see Jaken (1996) ; Mochly-Rosen and Kauvar (1998); Nishizuka (1995) ). Conventional PKCs (a, b1, b2, g) require negatively charged phospholipids, calcium and diacylglycerol (DAG) for optimal activity whereas novel PKCs (d, e, Z/L, y) require only phospholipids and DAG. Members of both these groups are also activated by phorbol esters such as TPA which interact with the same site as DAG and eliminate the need for other cofactors. Atypical PKCs (z, l/i, m) do not require either calcium or DAG for maximal activity and are not activated by phorbol esters.
In order to better understand the signaling pathways involved in the FGF-2-stimulated proliferation of ®broblasts, we investigated the eect of TPA on their proliferative response to FGF-2. Similar to the vascular smooth muscle and endothelial cells, we found that TPA eectively inhibits the FGF-2-stimulated proliferation of ®broblasts. Furthermore, we found that this inhibition appears to be due to the inhibition of p38 MAPK activation. Thus, the studies described here not only provide further evidence for a critical role for p38 MAPK in the FGF-2-stimulated proliferation of ®broblasts but also demonstrate how the regulation of this kinase by other signaling proteins can modulate the eect of FGF-2 on cells.
Results
To determine the role of PKC activation in the FGF-2-induced proliferation of ®broblasts, Swiss 3T3 cells were treated with FGF-2 in the absence or presence of various doses of the phorbol ester, TPA. As shown in Figure 1 , concentrations of TPA as low as 10 ng/ml signi®cantly reduced FGF-2-stimulated cell proliferation. In contrast, TPA greatly enhanced the basal level of cell proliferation and slightly enhanced PDGFstimulated proliferation while having little or no eect on serum-induced proliferation (Figure 1 ). These data suggest that PKC activation speci®cally inhibits a signaling pathway required for FGF-2-induced ®bro-blast proliferation but not proliferation stimulated by either PDGF or serum.
Recently, work from this laboratory demonstrated that p38 MAPK activation was speci®cally required for FGF-2-induced proliferation of ®broblasts (Maher, 1999) . To determine if the inhibitory eect of PKC activation on FGF-2-induced proliferation could be mediated by its action on p38 MAPK activation, Swiss 3T3 ®broblasts were pretreated with TPA for 0 ± 60 min prior to the addition of FGF-2 and then p38 MAPK activation monitored by immunoblotting with antibodies to the dually phosphorylated and thereby active form of the kinase. As shown in Figure 2a , pretreatment of the cells with TPA led to a time dependent decrease in p38 MAPK activation. Figure  2b shows the dose dependence of the TPA eect on FGF-2-stimulated p38 MAPK activation which closely matches the dose dependence of the eect on FGF-2-induced cell proliferation. TPA alone had only a slight eect on p38 MAPK activation (Figure 2a,b) . Although TPA also inhibited p38 MAPK activation induced by treatment of Swiss 3T3 ®broblasts with serum ( Figure 2c ), p38 MAPK activation does not appear to be required for serum-induced ®broblast proliferation (Maher, 1999) which is consistent with the minimal eect of TPA on serum-stimulated Swiss 3T3 cell proliferation (Figure 1) .
To con®rm that the TPA-mediated decrease in p38 MAPK activation as determined by immunoblotting with anti-phospho p38 MAPK antibodies corresponded to a decrease in p38 MAPK activity, the eect of TPA on the activation of MAPKAP kinase-2, a speci®c and direct downstream substrate of p38 MAPK kinase in ®broblasts (Maher, 1999) and other cells (Cohen, 1997) , was determined. As shown in Figure 2c , TPA treatment signi®cantly reduced FGF-2-stimulated MAPKAP kinase-2 activation with a similar dose dependence to that seen for the inhibition of both FGF-2-stimulated p38 MAPK phosphorylation and ®broblast proliferation. Furthermore, the level of reduction in MAPKAP kinase-2 activity brought about by TPA treatment was very similar to the level of reduction in p38 MAPK activation as determined by immunoblotting with anti-phospho p38 MAPK antibodies, as well as the degree of inhibition of cell proliferation. Figure 1 The eects of TPA treatment on the proliferation of ®broblasts. Quiescent Swiss 3T3 ®broblasts were untreated (ct) or treated for 24 h with 5 ng/ml FGF-2, 5 ng/ml PDGF or 10% serum in the absence or presence of the indicated concentrations of TPA and then labeled with 3 H-thymidine and radioactive label incorporation analysed by liquid scintillation counting. The results are presented as the per cent of the cell proliferation seen with the growth factor alone or, in the case of untreated cells, the per cent of the basal cell proliferation and are the average of 3 ± 5 independent experiments with each treatment run in triplicate. The average fold stimulation of proliferation by FGF-2 alone was 6.8+3.6, by PDGF alone was 5.4+2.5 and by serum alone was 19.1+7.2
To determine if the eect of TPA on p38 MAPK activation is speci®c to this kinase or is the result of a general eect of TPA treatment on FGF-2 receptor activation, the overall pattern of protein tyrosine phosphorylation in the Swiss 3T3 ®broblasts following FGF-2 treatment in the absence or presence of TPA was examined (Figure 3a) . TPA had no eect on the overall pattern of FGF-2-induced protein tyrosine Figure 2 TPA blocks p38 MAPK activation by FGF-2. (a) Time course of the TPA-mediated inhibition of FGF-2-stimulated p38 MAPK activation. Quiescent Swiss 3T3 cells were untreated (ct) or treated with FGF-2 (25 ng/ml) for 5 min following no pretreatment (FGF) or a 0, 5, 10, 30 or 60 min pretreatment with 100 ng/ml TPA. Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for the activated form (phospho Thr180/Tyr182) of p38 MAP kinase and total p38 MAPK. Similar results were obtained in four independent experiments. (b) Dose dependence of the TPA-mediated inhibition of FGF-2-stimulated p38 MAPK activation. Quiescent Swiss 3T3 cells were untreated (ct) or treated with FGF-2 (25 ng/ml) for 5 min following no pretreatment (FGF) or a 60 min pretreatment with 5, 10, 25, 50 or 100 ng/ml TPA. Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated p38 MAP kinase and total p38 MAPK. Similar results were obtained in four independent experiments. (c) TPA treatment inhibits p38 MAPK activation by serum. Quiescent Swiss 3T3 cells were untreated (ct), treated with 100 ng/ml TPA for 60 min (TPA), treated with 10% serum for 10 min (ser) or pretreated with TPA for 60 min prior to the treatment with serum (TPA/ser). Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated p38 MAP kinase and total p38 MAPK. Similar results were obtained in two independent experiments. (d) TPA treatment blocks the activation of MAPKAP kinase-2, a speci®c and direct substrate of p38 MAPK, by FGF-2 treatment. Quiescent Swiss 3T3 cells were treated with FGF-2 (25 ng/ml) following no pretreatment (0) or a 60 min pretreatment with the indicated concentrations of TPA (10, 50, 100 ng/ml). The cells were then solubilized in MAPKAP kinase 2 buer, MAPKAP kinase-2 was immunoprecipitated from the extracts and the kinase activity was assayed using a peptide substrate and liquid scintillation counting. The results represent the average of 3 ± 5 independent experiments Figure 3 Eects of TPA treatment on FGF receptor activation and function. (a) Quiescent Swiss 3T3 cells were untreated (ct), treated with FGF-2 (25 ng/ml) for 5 min (FGF), treated with 100 ng/ml TPA for 60 min (TPA) or pretreated with TPA for 60 min prior to the treatment with FGF-2 (TPA/FGF). Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with an antibody speci®c for activated p38 MAP kinase, antibodies speci®c for activated ERKs (Thr 202/Tyr204) and total ERKs, antibodies speci®c for activated p70 S6 kinase (Thr421/Ser424) and total p70 S6 kinase or an anti-phosphotyrosine antibody (ptyr). Similar results were obtained in three independent experiments. (b) Swiss 3T3 cells were treated with TPA (100 ng/ml) for 60 min and the binding of 1251-FGF-2 was assayed as described in Materials and methods. The results represent the average of three independent experiments with each treatment done in triplicate phosphorylation suggesting that TPA was not having a general eect on FGF receptor signaling. Furthermore, the activation of two downstream kinases which have been shown to be required for FGF-2-induced cell proliferation in ®broblasts and/or other cell types was not aected by TPA treatment. As shown in Figure 3a , neither FGF-2-stimulated p70S6 kinase activation nor ERK activation was aected by TPA treatment. Consistent with the lack of an eect of TPA treatment on FGF-2-stimulated protein tyrosine phosphorylation, TPA treatment also had only a modest eect on FGF-2 binding to Swiss 3T3 cells (Figure 3b) To con®rm that the eects of TPA treatment were mediated by the activation of PKC, two approaches were taken. In the ®rst approach, a high dose of TPA was used to downregulate TPA-sensitive PKC isoforms (see Figure 5 ) and in the second approach, a PKC inhibitor speci®c for all PKC isozymes except PKCm (Zeidman et al., 1999) was used. Figure 4 demonstrates that both treatments prevent the TPA-mediated inhibition of FGF-2-dependent p38 MAPK activation as determined by both immunoblotting with antiphospho p38 MAPK antibodies ( Figure 4a ) and by assays for MAPKAP kinase 2 activation ( Figure 4b ). In addition, Go6983 relieved the inhibition of FGF-2-stimulated cell proliferation brought about by TPA treatment ( Figure 4c ). Go6983 had no eect on the expression of the dierent PKC isozymes (data not shown).
To further investigate the eect of TPA treatment on the FGF-2-dependent stimulation of p38 MAPK activity, it was necessary to determine which PKC isoforms could be involved. Swiss 3T3 ®broblasts express the conventional PKC isoform a, the novel PKC isoforms d and e and the atypical PKC isoforms l, z and m ( Figure 5 ). They do not express PKCb, g, y, or Z. As expected, PKCa, d and e can be downregulated by extended treatment with a high dose of TPA, whereas the atypical isoforms are insensitive to this regimen ( Figure 5 ). To determine which of the three TPA-sensitive PKC isoforms expressed in Swiss 3T3 cells is most likely to mediate the eects of TPA on FGF-2-stimulated p38 MAPK activation, the eects of dierent doses of TPA on PKC isoform downregulation and p38 MAPK activation were determined. As shown in Figures 5 and 6a , treatment of the cells with either 100 ng/ml or 1 mg/ml TPA for 24 h downregulated PKCa, d and e and alleviated the inhibition of p38 MAPK activation. In contrast, treatment of the cells with 10 ng/ml TPA for 24 h only downregulated PKCd ( Figure 5 ) and had little eect on the TPA-mediated inhibition of p38 MAPK activation ( Figure 6a ). Thus, PKCd activity does not appear to play a dominant role in the inhibition of p38 MAPK activation. This result was supported by the minimal eect of the relatively speci®c PKCd inhibitor, Figure 4 Eect of PKC downregulation and the PKC inhibitor Go6983 on the TPA-mediated inhibition of FGF-2-stimulated p38 MAPK activation. (a) Quiescent Swiss 3T3 cells were untreated (Ct) or treated with FGF-2 (25 ng/ml) for 5 min following no pretreatment (FGF) or a 60 min pretreatment with 100 ng/ml TPA (TPA; TPA/FGF). In some cases, cells were pretreated for 24 h with 1 mg/ml TPA (TPA-DR) or for 1 h with 1 mM Go6983 (Go) prior to the addition of TPA and/or FGF-2. Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated p38 MAP kinase and total p38 MAPK. Similar results were obtained in three independent experiments. (b) Quiescent Swiss 3T3 cells were untreated (Ct) or treated with FGF-2 (25 ng/ml) following no pretreatment (FGF) or a 60 min pretreatment with 100 ng/ml TPA (TPA; TPA/FGF). In some cases, the cells were pretreated for 24 h with 1 mg/ml TPA (TPA-DR) or for 1 h with 1 mM Go6983 (Go6983) prior to the pretreatment with TPA and/or the addition of FGF-2. The cells were then solubilized in MAPKAP kinase 2 buer, MAPKAP kinase-2 was immunoprecipitated from the extracts and the kinase activity was assayed using a peptide substrate and liquid scintillation counting. The results represent the average of 3 ± 5 independent experiments. (c) The PKC inhibitor Go6983 relieves the TPA-mediated inhibition of FGF-2-stimulated cell proliferation. Quiescent Swiss 3T3 ®broblasts were treated for 24 h with 5 ng/ml FGF-2 in the absence (FGF) or presence of 50 ng/ml TPA (TPA/FGF) and/or 1 mM Go6983 (Go6983/FGF; Go6983/TPA/FGF) and then labeled with 3 H-thymidine and radioactive label incorporation analysed by liquid scintillation counting. The results are presented as the fold stimulation of cell proliferation relative to quiescent, untreated cells and are the average of 3 ± 5 independent experiments with each treatment run in quadruplicate rottlerin, on the inhibition of p38 MAPK activation by TPA treatment (Figure 6b ). These data, in turn, suggest that only PKCa and PKCe are likely to play major roles in the TPA-mediated inhibition of p38 MAPK activation. Eorts to further distinguish between the roles of PKCa and PKCe using the Ca 2+ chelator, BAPTA-AM (Traub et al., 1997) , which should inhibit Ca 2+ -dependent PKCa but not Ca 2+ -independent PKCe, were unsuccessful because BAPTA-AM alone aected p38 MAPK activation.
A number of studies have shown that TPA treatment of cells can result in the activation of ERKs (ElShemerly et al., 1997; Schonwasser et al., 1998) and some studies have suggested that ERK activity can aect p38 MAPK activity. To determine if the eect of TPA treatment on p38 MAPK activity is mediated through ERKs, TPA-stimulated ERK activation was inhibited by treatment of the cells with the MEK inhibitor PD98059. PD98059 has little or no eect on FGF-2-stimulated ERK activation in the Swiss 3T3 ®broblasts (Maher (1999) and Figure 7 ) and so any eects of this treatment are unlikely to be due to direct eects on FGF-2-stimulated ERK activation. As shown in Figure 7 , treatment of the cells with PD98059 eciently blocked TPA-stimulated ERK activation and partially reduced the TPA-mediated inhibition of p38 MAPK activation as determined by both immunoblotting with anti-phospho p38 MAPK antibodies ( Figure 7a ) and by assays for MAPKAP kinase 2 activation (Figure 7b ). These data suggest that while the eect of TPA treatment on FGF-2-stimulated p38 MAPK activation is partially mediated by ERKs, it is also likely to require input from other downstream signaling pathways.
The ®nding that TPA treatment results in an inhibition of p38 MAPK activation suggests that TPA may be activating one or more phosphatases that can act on p38 MAPK. Three families of phosphatases have the potential to dephosphorylate p38 MAPK (for review see Keyse (1999) ) since active p38 MAPK is phosphorylated on both threonine and tyrosine and removal of just one of the two phosphates results in inactivation of the kinase. Thus, protein tyrosine phosphatases, serine/threonine phosphatases and dual speci®city phosphatases all have the potential to inactivate p38 MAPK. To determine if one of more of these phosphatases is involved in the TPA-mediated inhibition of FGF-2-stimulated p38 MAPK activation, the eects of several dierent phosphatase inhibitors with distinct speci®cities were tested. As shown in Figure 8a , both sodium orthovanadate, an inhibitor of both protein tyrosine phosphatases and dual speci®city phosphatases, and okadaic acid, an inhibitor of class 1 and 2A serine/threonine phosphatases (PP1/2A), greatly enhanced basal p38 MAPK activity and appeared to block the TPA-mediated inhibition of Figure 5 Analysis of PKC isozyme expression and downregulation in Swiss 3T3 cells. Quiescent Swiss 3T3 cells were untreated (ct) or treated for 24 h with 10, 100 or 1000 ng/ml TPA. The cells were scraped into sample buer and equal amounts of protein analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for each of the indicated PKC isozymes. Similar results were obtained in two independent experiments Figure 6 Characterization of the PKC isozymes involved in the TPA-mediated inhibition of p38 MAPK activation. (a) Quiescent Swiss 3T3 cells were untreated (ct) or treated with FGF-2 (25 ng/ ml) following no pretreatment (FGF) or a 60 min pretreatment with 10, 100 or 1000 ng/ml TPA (TPA/FGF). In some cases, cells were pretreated for 24 h with 10, 100 or 1000 ng/ml TPA prior to the addition of FGF alone (TPA O/N/FGF) or TPA for 60 min followed by FGF (TPA O/N/TPA/FGF). Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated p38 MAP kinase and total p38 MAPK. Similar results were obtained in three independent experiments. (b) PKCd is not required for the TPA-mediated inhibition of p38 MAPK activation. Quiescent Swiss 3T3 cells were untreated (ct) or treated with FGF-2 (25 ng/ml) following no pretreatment (FGF) or a 60 min pretreatment with 100 ng/ml TPA (TPA/FGF). In some cases, cells were pretreated for 1 h with the PKCd inhibitor rottlerin (1 mM) prior to the addition of FGF alone (rott/FGF) or TPA for 60 min followed by FGF (rott/TPA/FGF). Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated p38 MAP kinase and total p38 MAPK and antibodies speci®c for activated and total ERKs. Similar results were obtained in three independent experiments p38 MAPK activation. In contrast, cyclosporin, an inhibitor of calcineurin (PP2B), had no eect on either the basal phosphorylation of p38 MAPK or the TPAmediated inhibition of p38 MAPK activation ( Figure  8b ). When the eects of these phosphatase inhibitors were further investigated using MAPKAP kinase 2 activity as an endpoint, it became apparent that while both okadaic acid and sodium orthovanadate both greatly increased the basal levels of p38 MAPK activity, only sodium orthovanadate blocked the TPA-mediated inhibition of p38 MAPK activity (Figure 8c ). To provide further evidence that TPA activates a sodium orthovanadate-sensitive phosphatase which can dephosphorylate p38 MAPK, phosphatase activity was Figure 7 The eect of TPA on FGF-2-stimulated p38 MAPK activation is partially mediated by ERKs. (a) Quiescent Swiss 3T3 cells were untreated (ct) or treated with FGF-2 (25 ng/ml) following no pretreatment (FGF) or a 60 min pretreatment with 100 ng/ml TPA (TPA/FGF). In some cases, cells were pretreated for 1 h with the MEK inhibitor PD98059 (100 mM; PD) or the PKC inhibitor Ro318220 (1 mM; Ro) prior to the addition of FGF alone (PD/FGF; Ro/FGF) or TPA for 60 min followed by FGF (PD/TPA/FGF; Ro/TPA/FGF). Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated and total p38 MAP kinase and antibodies speci®c for activated ERKs. Similar results were obtained in three independent experiments. (b) Quiescent Swiss 3T3 cells were untreated (Ct) or treated with FGF-2 (25 ng/ml) following no pretreatment (FGF) or a 60 min pretreatment with 100 ng/ml TPA (TPA/FGF). In some cases, the cells were pretreated for 1 h with 100 mM PD98059 (PD) prior to the addition of TPA and/or FGF-2. The cells were then solubilized in MAPKAP kinase 2 buer, MAPKAP kinase-2 was immunoprecipitated from the extracts and the kinase activity was assayed using a peptide substrate and liquid scintillation counting. The results represent the average of 3 ± 5 independent experiments Figure 8 Phosphatase inhibitors block the TPA-mediated inhibition of p38 MAPK activation. (a) Quiescent Swiss 3T3 cells were untreated (ct) or treated with FGF-2 (25 ng/ml) following no pretreatment (FGF) or a 60 min pretreatment with 100 ng/ml TPA (TPA/FGF). In some cases, cells were pretreated for 1 h with 1 mM Na 3 VO 4 (VO 4 ) or 1 mM okadaic acid (OK) prior to the addition of FGF alone (VO 4 /FGF; OK/FGF) or TPA for 60 min followed by FGF (VO 4 /TPA/FGF; OK/TPA/FGF). Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated and total p38 MAP kinase. Similar results were obtained in three independent experiments. (b) Quiescent Swiss 3T3 cells were untreated (ct) or treated with FGF-2 (25 ng/ml) following no pretreatment (FGF) or a 60 min pretreatment with 100 ng/ml TPA (TPA/FGF). In some cases, cells were pretreated for 1 h with 1 mM cyclosporin (cyclo) prior to the addition of FGF alone (cyclo/FGF) or TPA for 60 min followed by FGF (cyclo/TPA/FGF). Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated and total p38 MAP kinase. Similar results were obtained in three independent experiments. (c) Quiescent Swiss 3T3 cells were untreated (ct) or treated with FGF-2 (25 ng/ml) following no pretreatment (FGF) or a 60 min pretreatment with 100 ng/ml TPA (TPA/FGF). In some cases, cells were pretreated for 1 h with 1 mM Na 3 VO 4 (VO 4 ), 1 mM okadaic acid (OK) or 1 mM cyclosporin (cyclo) prior to the addition of FGF alone (VO 4 /FGF; OK/FGF; cyclo/FGF) or TPA followed by FGF (VO 4 /TPA/FGF; OK/TPA/FGF; cyclo/ TPA/FGF). The cells were then solubilized in MAPKAP kinase 2 buer, MAPKAP kinase-2 was immunoprecipitated from the extracts and the kinase activity was assayed using a peptide substrate and liquid scintillation counting. The results represent the average of three independent experiments determined in cell extracts from untreated and TPAtreated cells using an assay which can measure both protein tyrosine phosphatase (Maher, 1993) and dual speci®city phosphatase activity (Misra-Press et al., 1995) . As shown in Figure 9 , treatment of cells with TPA resulted in a time dependent increase in phosphatase activity which is consistent with the time dependent decrease in p38 MAPK phosphorylation (Figure 2) .
Finally, it was asked if the eect of TPA on p38 MAPK activation was speci®c to FGF-2 signaling and, if so, if it was restricted to a speci®c cellular response to FGF-2 such as proliferation. To address the ®rst question, the eect of TPA treatment on p38 MAPK activation induced by several classical inducers of p38 MAPK, including anisomycin, sorbitol and H 2 O 2 , was tested. As shown in Figure 10 , TPA had little or no eect on the activation of p38 MAPK by either sorbitol or anisomycin but did reduce the activation by H 2 O 2 by *50%. Thus, the TPA eect is speci®c to only a subset of inducers of p38 MAPK.
To address the second question, the eect of TPA treatment on p38 MAPK activation in PC12 cells was examined. Although these cells express the same FGF receptor as the Swiss 3T3 ®broblasts (Maher, 1999) , they dierentiate rather than proliferate in response to FGF-2 treatment ( (Sigmund et al. (1990) and data not shown). In contrast to the eects of TPA in the Swiss 3T3 ®broblasts, TPA treatment enhanced rather than inhibited p38 MAPK activation in the PC12 cells (Figure 11a ). This enhancement was con®rmed in Figure 9 The eect of TPA on phosphatase activity. Quiescent Swiss 3T3 cells were untreated (0) or treated for 2.5 ± 60 min with 100 ng/ml TPA. Cell extracts were prepared and 5 mg of each extract were assayed for phosphatase activity as described (Maher, 1993 ) using g-32 P-labeled Raytide as the substrate. In some cases (TPA-DR), cells were pretreated for 24 h with 1 mg/ml TPA to downregulate PKC prior to the addition of 100 ng/ml TPA for 60 min. The results represent the average of three independent experiments Figure 10 The eect of TPA on p38 MAPK activation induced by classical activators of the p38 MAPK pathway. Quiescent Swiss 3T3 cells were untreated (ct) or treated with 25 ng/ml FGF-2 (FGF) for 5 min, 300 mM sorbitol (sorb) for 30 min, 10 mg/ml anisomycin (anis) for 30 min or 1 mM H 2 O 2 (H 2 O 2 ) for 30 min alone or following a 60 min pretreatment with 100 ng/ml TPA (TPA/FGF; TPA/sorb; TPA/anis; TPA/H 2 O 2 ). Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated p38 MAP kinase and total p38 MAPK. Similar results were obtained in three independent experiments Figure 11 The eect of TPA on FGF-2-stimulated p38 MAPK activation in PC12 cells. (a) PC12 cells in N2 medium were untreated (ct) or treated with FGF-2 (25 ng/ml) for 5 min following no pretreatment (FGF) or a 60 min pretreatment with 5, 10, 25, 50, 100 or 200 ng/ml TPA. Cell extracts were prepared and equal amounts of protein were analysed by SDS ± PAGE and immunoblotting with antibodies speci®c for activated p38 MAP kinase and total p38 MAPK. Similar results were obtained in three independent experiments. (b) PC12 cells in N2 medium were treated with FGF-2 (25 ng/ml) following no pretreatment (0) or a 60 min pretreatment with the indicated concentrations of TPA (5, 10, 50, 100 ng/ml). The cells were then solubilized in MAPKAP kinase 2 buer, MAPKAP kinase-2 was immunoprecipitated from the extracts and the kinase activity was assayed using a peptide substrate and liquid scintillation counting. The results represent the average of 3 ± 5 independent experiments MAPKAP kinase 2 assays (Figure 11b ). TPA had no eect on the FGF-2-stimulated dierentiation of PC12 cells (data not shown), as reported previously (Sigmund et al., 1990) .
Discussion
The results presented here demonstrate that TPA treatment speci®cally inhibits the FGF-2-induced proliferation of ®broblasts and that this inhibition is at least partially mediated by the TPA-dependent inactivation of p38 MAPK. TPA treatment has been shown previously to inhibit the basal growth of several dierent cell types, including melanoma-derived cells (Arita et al., 1994) and certain ®broblast lines (Huang et al., 1995) . In addition, several studies found that TPA treatment could reduce the mitogenic response of endothelial cells (Presta et al., 1998) or vascular smooth muscle cells (Weiss et al., 1995) to FGF-2. However, this is the ®rst demonstration that TPA treatment inhibits the proliferative response of ®bro-blasts to FGF-2 and that it appears to do so by reducing the activation of p38 MAPK.
PKC activation has been frequently associated with the stimulation of cell proliferation (for reviews see Deacon et al. (1997) ; Mochly-Rosen and Kauvar (1998)). Indeed, rat embryo ®broblasts which overexpress PKCb1 show an increase in saturation density and a loss of anchorage dependence while ®broblasts which overexpress PKCe are transformed and highly tumorigenic in nude mice (Weinstein et al., 1997) . Furthermore, TPA, along with other phorbol esters, is a tumor promoter indicating that treatment of cells with this agent can lead to a loss of growth control. However, certain cell types appear to show a dierent response to TPA treatment, namely the inhibition of proliferation. This inhibition has been proposed to be cell type dependent (Huang et al., 1995) , suggesting that it is related to the speci®c pattern of PKC isoforms expressed in a given cell type. However, the results presented here demonstrate that even in a single cell type, TPA treatment can have opposing eects on the response of the cell to dierent mitogens. Furthermore, the mechanism of inhibition appears to be distinct from that proposed previously for FGF responsiveness in endothelial cells and vascular smooth muscle cells. In endothelial cells, the inhibition of FGF stimulated proliferation by TPA treatment was co-incident with a 60% decrease in FGF binding to the cell surface (Presta et al., 1998) . This response of endothelial cells to TPA treatment is similar to the transmodulation of the EGF receptor (EGFR) by PKC activation which also results in the inhibition of high anity EGF binding to the EGFR, as well as the downregulation of EGFstimulated EGFR kinase activity (Presta et al., 1998; Zachary and Rozengurt, 1985) . However, TPA treatment causes only a slight decrease FGF-2 binding to Swiss 3T3 cells and does not alter FGF-2-stimulated receptor kinase activity (Figure 3) . In contrast, in vascular smooth muscle cells, the TPA-mediated inhibition of FGF-induced mitogenesis was associated with a decrease in phosphatidylinositol 3-kinase (PI3K) activation (Weiss and Yabes, 1996) . The role of PI3K in FGF-2-stimulated cell proliferation is unclear (e.g. Cross et al. (2000) ; Kanda et al. (1997) ; Raoni and Bradshaw (1992) ). However, PI3K is involved in the activation of p70S6 kinase. p70S6 kinase is one of the few enzymes that has been shown to be important for FGF-2-induced proliferation of endothelial cells (Kanda et al., 1997) and Swiss 3T3 ®broblasts (unpublished data). p70S6 kinase is required for the selective translation of a speci®c family of mRNAs which encode components of the translational apparatus. The increased expression of these proteins is essential for cell growth and proliferation (for reviews see Chou and Blenis (1995) ; Dufner and Thomas (1999) ). However, the activation of p70S6 kinase is not aected by TPA treatment indicating that this is not the site of action for the TPA-dependent inhibition of FGF-2-induced ®broblast proliferation. ERKs have also been shown to be required for FGF-2-induced proliferation of speci®c cell types (SkaletzRorowski et al., 1999; Tanaka et al., 1999) , although their role in ®broblast proliferation is unclear (compare Maher (1999) ; Pages et al. (1993) ). However, ERK activation is also not inhibited by TPA treatment.
In contrast, p38 MAPK activation is inhibited by TPA treatment. p38 MAPK was recently shown to be required for the FGF-2-induced proliferation of both ®broblasts (Maher, 1999) and endothelial cells (Tanaka et al., 1999) . p38 MAPK was ®rst identi®ed several years ago in lipopolysaccharide-stimulated mouse macrophages (Han et al., 1994) and was shown to be the target of a series of anti-in¯ammatory pyridinyl imidazole compounds . Four dierent isoforms (a, b, g, d) of this kinase, which can be distinguished on the basis of inhibitor and substrate speci®city, have now been characterized (for reviews see Lewis et al. (1998); Tibbles and Woodgett (1999) ). Since only p38 MAPKa is both inhibited by the pyridinyl imidazole SB203580 and capable of phosphorylating MAPKAP kinase 2 (Enslen et al., 1998; Wang et al., 1997) , it is likely that this p38 MAPK isoform is required for FGF-2-induced ®broblast proliferation. Although p38 MAPK activation has generally been associated with the cellular response to stress, a number of reports have suggested additional roles for this kinase in placental angiogenesis (Mudgett et al., 2000) , growth hormone-stimulated mitogenesis (Zhu and Lobie, 2000) , the promotion of cell hypertrophy Zechner et al., 1997) and hemopoietic (Foltz et al., 1997) and T-cell (Crawley et al., 1997) proliferation. Thus, the involvement of p38 MAPK in FGF-2-induced ®broblast proliferation is not without precedent.
One strong possibility for the inactivation of p38 MAPK by TPA is that it is through one of the members of the MAP kinase phosphatase (MKP) family (for review see Keyse (1999) ). This possibility is supported by both the data with the tyrosine phosphatase inhibitor, sodium orthovanadate ( Figure  8 ), which also inhibits MKPs, and the results of the phosphatase assay (Figure 9 ). The dierent members of the MKP family exhibit distinct cellular locations and substrate speci®city. For example, MKP-1 is localized to the nucleus and can dephosphorylate and inactivate ERKs, JNK and p38 MAPK, although recent work has shown that this MKP preferentially dephosphorylates JNK and p38 MAPK in vivo (Franklin and Kraft, 1997) . In contrast, MKP-3, MKP-4 and M3/6 are exclusively cytosolic. MKP-3 and -4 speci®cally dephosphorylate ERKs but M3/6 is only active towards JNK and p38 MAPK. Furthermore, TPA treatment of cells can induce the synthesis of MKP-1 (Kwak et al., 1994) by a pathway which requires ERK activity (Franklin and Kraft, 1997) . Although it is unlikely that TPA treatment of the Swiss 3T3 cells is inducing de novo synthesis of MKP-1 since the downregulation of p38 MAPK phosphorylation is apparent within 5 min following the addition of TPA to cells (Figure 2a ), TPA could be directly or indirectly activating this or a related phosphatase. Furthermore, since TPA-dependent p38 MAPK inactivation is at least partially dependent on ERK activity (Figure 7) , this suggests that, in the ®broblasts, ERKs could regulate the activity of MKP or a related phosphatase through a process that does not require new protein synthesis. Alternatively, the TPA-dependent inactivation of p38 MAPK may be mediated by a protein tyrosine phosphatase which speci®cally acts on p38 MAPK. Recently, a role for protein tyrosine phosphatases in the actions of PKC in T-cells was demonstrated (Tsuchida et al., 2000) .
The observation that the eect of TPA on p38 MAPK activity is seen only with a subset of p38 MAPK inducers (Figure 10 ) suggests that phosphatase activity may play a relatively more important role in regulating p38 MAPK activity in response to FGF-2 and H 2 O 2 than in response to sorbitol and anisomycin. This result is consistent with a recent study on a related MAPK family member, JNK, which showed that certain agents, including oxidative stress, but not anisomycin or osmotic stress, activate JNK not by turning-on an upstream kinase pathway but rather by inhibiting JNK dephosphorylation (Meriin et al., 1999) . Thus, it is possible that the ability of TPA to promote the dephosphorylation of p38 MAPK is only apparent with agents which regulate this kinase predominantly through their actions on a p38 MAPK phosphatase. Further studies will be needed to determine if this is indeed the case.
TPA speci®cally inhibits the FGF-2-induced proliferation of ®broblasts but does not block proliferation induced by either PDGF or serum (Figure 1 ), nor does it aect the FGF-2-induced dierentiation of PC12 cells (data not shown and Sigmund et al. (1990) ). These eects of TPA are consistent with an action on a signaling pathway which is speci®cally required for the FGF-2-induced proliferation of ®broblasts such as p38 MAPK. p38 MAPK is not required for the serumstimulated proliferation of ®broblasts (Maher, 1999) or the PDGF-induced proliferation of endothelial cells (Matsumoto et al., 1999) . p38 MAPK is also not required for the FGF-2-mediated dierentiation of PC12 cells (Maher, 1999) . Thus, the speci®c eects of TPA on FGF-2-induced ®broblast proliferation appear to mediate by a signaling protein which is unique to this proliferative pathway. Although the consequences of the activation of these dierent signaling pathways may be very similar in terms of gene expression (e.g. Fambrough et al. (1999) ), the results presented here support the idea that there are multiple ways to achieve the same outcome. This leaves open the possibility of speci®cally targeting individual growth factor signaling pathways so that the responses of cells to other mitogens remain unaected.
In summary, the work presented here demonstrates that TPA activation blocks the FGF-2-induced proliferation of ®broblasts in a stimulus-dependent manner since the response to other mitogenic agents is not aected. Furthermore, this inhibition appears to be mediated by the ERK-dependent inactivation of p38 MAPK, an enzyme that is speci®cally required for FGF-2-stimulated ®broblast proliferation.
Materials and methods

Materials
PD98059 was obtained from Biomol and solubilized in DMSO. SB203580, Go6983 and Ro318220 were obtained from Calbiochem and solubilized in DMSO. TPA was obtained from Sigma and solubilized in ethanol. Recombinant human FGF-2 was prepared as described (Lappi et al., 1994) . PDGF was purchased from R&D Systems.
Cell culture
Swiss 3T3 cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and grown in Dulbecco's modi®ed Eagle's medium (DME; Gibco) supplemented with 10% calf serum (Hyclone) and antibiotics. To examine the eects of FGF-2 or other growth factors on the Swiss 3T3 cells, they were grown to con¯uency and then made quiescent by washing with serum-free DME followed by incubation for 2 days in DME with 0.5% calf serum. PC12 cells were obtained from D Schubert (Salk Institute) and maintained in DME supplemented with 10% fetal calf serum (Hyclone), 5% horse serum (Hyclone) and antibiotics. To examine the eects of FGF-2 on the PC12 cells, the culture medium was removed and replaced by the chemically de®ned N2 medium (Gibco).
Stimulation with growth factors
Quiescent Swiss 3T3 cells or PC12 cells in N2 medium were treated with the growth factors and other agents as described in the ®gure legends and, after the indicated time periods, the cells were solubilized in SDS-sample buer containing 0.1 mM Na 3 VO 4 and 1 mM PMSF, boiled for 5 min and either analysed immediately or stored frozen at 7708C.
SDS ± PAGE and immunoblotting
Proteins were separated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose. Transfers were blocked for 2 h at room temperature with 5% nonfat milk in TBS/0.1% Tween 20 (anti-ptyr; 2% milk) and then incubated overnight at 48C in the primary antibody diluted in 5% BSA in TBS/ 0.05% Tween 20. The primary antibodies used were: phosphospeci®c p38 MAPK antibody (#9211; 1/1000), phosphospeci®c MAPK antibody (#9101, 1/1000) and phosphospeci®c (Thr421/Ser424) p70S6 kinase antibody (#9204; 1/1000) from New England Biolabs; p38 MAP kinase antibody (#sc-728, 1/1000) and p70S6 kinase antibody (#sc-230, 1/1000) from Santa Cruz Biotechnology; pan ERK antibody (1/5000) and all the PKC antibodies from Transduction Laboratories. The rabbit anti-phosphotyrosine antibody was prepared as described (Pasquale et al., 1988) and used at 1 mg/ml. The transfers were rinsed with TBS/ 0.05% Tween 20 and incubated for 1 h at room temperature in horseradish peroxidase-goat anti-rabbit or goat anti-mouse (Biorad) diluted 1/5000 in 5% nonfat milk in TBS/0.1% Tween 20 (anti-ptyr; 2% milk). The immunoblots were developed with the Super Signal reagent (Pierce).
Measurement of the stimulation of DNA synthesis
Cells were grown in 96-well dishes (1610 4 cells/well) for 2 days in DME containing 10% calf serum, at which time they were con¯uent. After washing with serum-free DME, they were incubated for a further 2 days in DME with 0.5% calf serum. The rate of DNA synthesis was measured 24 h after the addition of growth factors and other agents to the cells by the addition of 0.2 mCi/well of [methyl-3 H]thymidine (6.7 Ci/mole, ICN), followed by incubation for 5 h. The cultures were then processed for scintillation counting as described (Pasquale et al., 1988) .
MAPKAP kinase-2 assay
Cells in 60 mm dishes were solubilized in 500 ml of 1% Triton X-100 in 50 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , 0.1% 2-mercaptoethanol, 5 mM sodium pyrophosphate, 10 mM b-glycerophosphate, 50 mM NaF, 1 mM PMSF, 1 mg/ml aprotinin, and 1 mg/ml leupeptin. MAPKAP kinase-2 in the supernatants was collected with sheep anti-rabbit MAPKAP kinase-2 (1.2 mg/immunoprecipitate; Upstate Biotechnology) preabsorbed to protein GSepharose. The immunoprecipitates were washed once with solubilization buer containing 500 mM NaCl, once with solubilization buer and once with kinase assay buer and resuspended in 30 ml kinase assay buer (20 mM MOPS, pH 7.2, 25 mM b-glycerophosphate, 5 mM EGTA, 1 mM Na 3 VO 4 , and 1 mM dithiothreitol) containing 25 mM MgCl 2 , 150 mM ATP, 10 mCi/assay [g-32 P]ATP (ICN) and 62.5 mM MAPKAP kinase-2 substrate peptide (Upstate Biotechnology). Following incubation at 308C for 30 min, the protein G-Sepharose beads were pelleted and the supernatants transferred to P81 phosphocellulose paper disks. The disks were washed 36 with 0.85% phosphoric acid, once with H 2 O and counted in a liquid scintillation counter.
Measurement of protein tyrosine phosphatase activity
Con¯uent, quiescent Swiss 3T3 cells on 60 mm dishes were treated for 0 ± 60 min with 100 ng/ml TPA. The cells were then rinsed twice with cold Tris-buered saline, scraped into 20 mM HEPES, pH 7.4, 350 mM sucrose, 150 mM KCl containing 25 mM PMSF, 2 mg/ml aprotinin, 1 mg/ml leupeptin (400 ml), sonicated for 10 s on ice and clari®ed by centrifugation at 16 000 g for 10 min at 48C. Protein tyrosine phosphatase activity in 5 mg of clari®ed cell lysate was assayed exactly as described (Maher, 1993) .
I-FGF-2 binding
125 I-FGF-2 was from Amersham (1000 Ci/mmol). Quiescent Swiss 3T3 cells were untreated or treated with TPA (100 ng/ ml) for 60 min and then rinsed twice in HEPES-buered DME followed by addition of HEPES-buered DME containing 0.2% gelatin.
125 I-FGF-2 was added (0.2 ± 10 ng/ ml) and the cells were incubated at 48C for 2 h with shaking. The cells were rinsed once with phosphate-buered saline, once with 2 M NaCl in 50 mM HEPES, pH 7.5 to remove 125 I-FGF-2 bound to low anity sites, again with phosphatebuered saline and then solubilized with 500 ml 1% Triton X-100 buer (1% Triton X-100, 50 mM HEPES, pH 7.5, 50 mM NaCl, 5 mM EDTA, 1 mM Na 3 VO 4 ) and counted in a gamma counter.
Abbreviations FGF, ®broblast growth factor; FGFR, ®broblast growth factor receptor; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; MEK, mitogenactivated protein/ERK kinase; PAGE, polyacrylamide gel electrophoresis, PBS, phosphate-buered saline; TBS, Trisbuered saline; PMSF, phenylmethylsulfonyl¯uoride; DMEM, Dulbecco's modi®ed minimal essential medium; MOPS, 4-morpholinepropanesulfonic acid; TPA, 12-Otetradecanoyl phorbol 13-acetate; PKC, protein kinase C; MKP, MAP kinase phosphatase; PI3K, phosphatidylinositol 3-kinase
